img

Global Non-corticosteroid Immunomodulator Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Non-corticosteroid Immunomodulator Market Research Report 2024

The primary types of non-corticosteroid immunomodulators include, calcineurin inhibitors, antiproliferative agents, mTOR inhibitors, and IMDH inhibitors among other drug classes.This is a drug class that inhibits the cell-cycle pathways to limit T- and B-cell proliferation to reduce the cytotoxic response directed toward an organ transplant such as cardiac allograft.Non-corticosteroid immunomodulators play a crucial role in the treatment of autoimmune diseases, inflammatory disorders, and certain types of cancer. Unlike corticosteroids, which have broad immunosuppressive effects, these immunomodulators selectively target specific components of the immune system to restore balance and regulate immune responses.
According to Mr Accuracy reports new survey, global Non-corticosteroid Immunomodulator market is projected to reach US$ 2304.3 million in 2029, increasing from US$ 1610 million in 2022, with the CAGR of 5.2% during the period of 2024 to 2029.
The global non-corticosteroid immunomodulator market refers to the overall market for medications that modulate the immune system without using corticosteroids. These medications are used to regulate and modify immune responses in various diseases and conditions where an immune system dysfunction is present.
Non-corticosteroid immunomodulators play a crucial role in the treatment of autoimmune diseases, inflammatory disorders, and certain types of cancer. Unlike corticosteroids, which have broad immunosuppressive effects, these immunomodulators selectively target specific components of the immune system to restore balance and regulate immune responses.
The market for non-corticosteroid immunomodulators has been growing significantly due to factors such as the increasing prevalence of autoimmune diseases, the rising demand for targeted therapies, and advancements in biotechnology and drug development. These immunomodulators offer potential benefits such as reduced adverse effects compared to corticosteroids and the ability to provide more precise immune regulation.
The market is segmented based on various factors, including type, application, end-user, and geography. Different types of non-corticosteroid immunomodulators include biologics (monoclonal antibodies, fusion proteins, cytokines), immunosuppressive drugs (calcineurin inhibitors, antimetabolites), and other small molecules.
Applications of non-corticosteroid immunomodulators span across various therapeutic areas, including autoimmune diseases (such as rheumatoid arthritis, multiple sclerosis, psoriasis), inflammatory bowel diseases, organ transplantation, dermatology, and oncology.
Healthcare providers, hospitals, and specialty clinics are the primary end-users of non-corticosteroid immunomodulators. In some cases, these medications may be used in combination with other therapies or as a monotherapy depending on the specific disease or condition.
Geographically, the market is divided into regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America and Europe account for a significant share of the global non-corticosteroid immunomodulator market due to advanced healthcare infrastructure, higher adoption of targeted therapies, and extensive research and development activities. The Asia Pacific region is expected to witness substantial growth owing to the increasing prevalence of autoimmune diseases, improving healthcare facilities, and rising healthcare expenditure.
Key players in the global non-corticosteroid immunomodulator market include pharmaceutical companies, biotechnology firms, and research organizations. These companies invest in research and development, clinical trials, and collaborations to develop novel immunomodulators and expand their product portfolios.
Market trends, growth rates, and competitive landscape may vary across different regions and specific types of non-corticosteroid immunomodulators. Factors such as patent expirations, regulatory approvals, and the emergence of biosimilars can influence the market dynamics.
In summary, the global non-corticosteroid immunomodulator market is expected to witness significant growth in the coming years due to the increasing demand for targeted therapies and the rising prevalence of autoimmune diseases. However, market conditions and growth rates may be influenced by factors such as pricing and reimbursement challenges, competition, and regulatory frameworks.The global non-corticosteroid immunomodulator market refers to the overall market for medications that modulate the immune system without using corticosteroids. These medications are used to regulate and modify immune responses in various diseases and conditions where an immune system dysfunction is present.
Non-corticosteroid immunomodulators play a crucial role in the treatment of autoimmune diseases, inflammatory disorders, and certain types of cancer. Unlike corticosteroids, which have broad immunosuppressive effects, these immunomodulators selectively target specific components of the immune system to restore balance and regulate immune responses.
The market for non-corticosteroid immunomodulators has been growing significantly due to factors such as the increasing prevalence of autoimmune diseases, the rising demand for targeted therapies, and advancements in biotechnology and drug development. These immunomodulators offer potential benefits such as reduced adverse effects compared to corticosteroids and the ability to provide more precise immune regulation.
The market is segmented based on various factors, including type, application, end-user, and geography. Different types of non-corticosteroid immunomodulators include biologics (monoclonal antibodies, fusion proteins, cytokines), immunosuppressive drugs (calcineurin inhibitors, antimetabolites), and other small molecules.
Applications of non-corticosteroid immunomodulators span across various therapeutic areas, including autoimmune diseases (such as rheumatoid arthritis, multiple sclerosis, psoriasis), inflammatory bowel diseases, organ transplantation, dermatology, and oncology.
Healthcare providers, hospitals, and specialty clinics are the primary end-users of non-corticosteroid immunomodulators. In some cases, these medications may be used in combination with other therapies or as a monotherapy depending on the specific disease or condition.
Geographically, the market is divided into regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America and Europe account for a significant share of the global non-corticosteroid immunomodulator market due to advanced healthcare infrastructure, higher adoption of targeted therapies, and extensive research and development activities. The Asia Pacific region is expected to witness substantial growth owing to the increasing prevalence of autoimmune diseases, improving healthcare facilities, and rising healthcare expenditure.
Key players in the global non-corticosteroid immunomodulator market include pharmaceutical companies, biotechnology firms, and research organizations. These companies invest in research and development, clinical trials, and collaborations to develop novel immunomodulators and expand their product portfolios.
Market trends, growth rates, and competitive landscape may vary across different regions and specific types of non-corticosteroid immunomodulators. Factors such as patent expirations, regulatory approvals, and the emergence of biosimilars can influence the market dynamics.
In summary, the global non-corticosteroid immunomodulator market is expected to witness significant growth in the coming years due to the increasing demand for targeted therapies and the rising prevalence of autoimmune diseases. However, market conditions and growth rates may be influenced by factors such as pricing and reimbursement challenges, competition, and regulatory frameworks.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Non-corticosteroid Immunomodulator market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


AbbVie Inc.
Bristol Myers Squibb Company
Celgene Corporation
Janssen Pharmaceuticals, Inc
Novartis AG
Amgen Inc.
Genentech, Inc.
Pfizer Inc.
Merck & Co., Inc.
Sanofi S.A.
Eli Lilly and Company
GlaxoSmithKline PLC
Mylan Laboratories Inc.
Glenmark Pharmaceuticals, Inc.
Novartis AG
Zydus Cadila
Takeda Pharmaceutical Company Limited
AstraZeneca PLC
Gilead Sciences, Inc.
Boehringer Ingelheim GmbH
Segment by Type
Calcineurin Inhibitors
Antiproliferative Agents
mTOR Inhibitors
IMDH Inhibitors
Others

Segment by Application


Organ Transplantation
Atopic Dermatitis
Crohn's Disease
Ulcerative Colitis
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Non-corticosteroid Immunomodulator report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-corticosteroid Immunomodulator Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Calcineurin Inhibitors
1.2.3 Antiproliferative Agents
1.2.4 mTOR Inhibitors
1.2.5 IMDH Inhibitors
1.2.6 Others
1.3 Market by Application
1.3.1 Global Non-corticosteroid Immunomodulator Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Organ Transplantation
1.3.3 Atopic Dermatitis
1.3.4 Crohn's Disease
1.3.5 Ulcerative Colitis
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-corticosteroid Immunomodulator Market Perspective (2018-2029)
2.2 Non-corticosteroid Immunomodulator Growth Trends by Region
2.2.1 Global Non-corticosteroid Immunomodulator Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Non-corticosteroid Immunomodulator Historic Market Size by Region (2018-2024)
2.2.3 Non-corticosteroid Immunomodulator Forecasted Market Size by Region (2024-2029)
2.3 Non-corticosteroid Immunomodulator Market Dynamics
2.3.1 Non-corticosteroid Immunomodulator Industry Trends
2.3.2 Non-corticosteroid Immunomodulator Market Drivers
2.3.3 Non-corticosteroid Immunomodulator Market Challenges
2.3.4 Non-corticosteroid Immunomodulator Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-corticosteroid Immunomodulator Players by Revenue
3.1.1 Global Top Non-corticosteroid Immunomodulator Players by Revenue (2018-2024)
3.1.2 Global Non-corticosteroid Immunomodulator Revenue Market Share by Players (2018-2024)
3.2 Global Non-corticosteroid Immunomodulator Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-corticosteroid Immunomodulator Revenue
3.4 Global Non-corticosteroid Immunomodulator Market Concentration Ratio
3.4.1 Global Non-corticosteroid Immunomodulator Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-corticosteroid Immunomodulator Revenue in 2022
3.5 Non-corticosteroid Immunomodulator Key Players Head office and Area Served
3.6 Key Players Non-corticosteroid Immunomodulator Product Solution and Service
3.7 Date of Enter into Non-corticosteroid Immunomodulator Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-corticosteroid Immunomodulator Breakdown Data by Type
4.1 Global Non-corticosteroid Immunomodulator Historic Market Size by Type (2018-2024)
4.2 Global Non-corticosteroid Immunomodulator Forecasted Market Size by Type (2024-2029)
5 Non-corticosteroid Immunomodulator Breakdown Data by Application
5.1 Global Non-corticosteroid Immunomodulator Historic Market Size by Application (2018-2024)
5.2 Global Non-corticosteroid Immunomodulator Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Non-corticosteroid Immunomodulator Market Size (2018-2029)
6.2 North America Non-corticosteroid Immunomodulator Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Non-corticosteroid Immunomodulator Market Size by Country (2018-2024)
6.4 North America Non-corticosteroid Immunomodulator Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-corticosteroid Immunomodulator Market Size (2018-2029)
7.2 Europe Non-corticosteroid Immunomodulator Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Non-corticosteroid Immunomodulator Market Size by Country (2018-2024)
7.4 Europe Non-corticosteroid Immunomodulator Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-corticosteroid Immunomodulator Market Size (2018-2029)
8.2 Asia-Pacific Non-corticosteroid Immunomodulator Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Non-corticosteroid Immunomodulator Market Size by Region (2018-2024)
8.4 Asia-Pacific Non-corticosteroid Immunomodulator Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-corticosteroid Immunomodulator Market Size (2018-2029)
9.2 Latin America Non-corticosteroid Immunomodulator Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Non-corticosteroid Immunomodulator Market Size by Country (2018-2024)
9.4 Latin America Non-corticosteroid Immunomodulator Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-corticosteroid Immunomodulator Market Size (2018-2029)
10.2 Middle East & Africa Non-corticosteroid Immunomodulator Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Non-corticosteroid Immunomodulator Market Size by Country (2018-2024)
10.4 Middle East & Africa Non-corticosteroid Immunomodulator Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Company Detail
11.1.2 AbbVie Inc. Business Overview
11.1.3 AbbVie Inc. Non-corticosteroid Immunomodulator Introduction
11.1.4 AbbVie Inc. Revenue in Non-corticosteroid Immunomodulator Business (2018-2024)
11.1.5 AbbVie Inc. Recent Development
11.2 Bristol Myers Squibb Company
11.2.1 Bristol Myers Squibb Company Company Detail
11.2.2 Bristol Myers Squibb Company Business Overview
11.2.3 Bristol Myers Squibb Company Non-corticosteroid Immunomodulator Introduction
11.2.4 Bristol Myers Squibb Company Revenue in Non-corticosteroid Immunomodulator Business (2018-2024)
11.2.5 Bristol Myers Squibb Company Recent Development
11.3 Celgene Corporation
11.3.1 Celgene Corporation Company Detail
11.3.2 Celgene Corporation Business Overview
11.3.3 Celgene Corporation Non-corticosteroid Immunomodulator Introduction
11.3.4 Celgene Corporation Revenue in Non-corticosteroid Immunomodulator Business (2018-2024)
11.3.5 Celgene Corporation Recent Development
11.4 Janssen Pharmaceuticals, Inc
11.4.1 Janssen Pharmaceuticals, Inc Company Detail
11.4.2 Janssen Pharmaceuticals, Inc Business Overview
11.4.3 Janssen Pharmaceuticals, Inc Non-corticosteroid Immunomodulator Introduction
11.4.4 Janssen Pharmaceuticals, Inc Revenue in Non-corticosteroid Immunomodulator Business (2018-2024)
11.4.5 Janssen Pharmaceuticals, Inc Recent Development
11.5 Novartis AG
11.5.1 Novartis AG Company Detail
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Non-corticosteroid Immunomodulator Introduction
11.5.4 Novartis AG Revenue in Non-corticosteroid Immunomodulator Business (2018-2024)
11.5.5 Novartis AG Recent Development
11.6 Amgen Inc.
11.6.1 Amgen Inc. Company Detail
11.6.2 Amgen Inc. Business Overview
11.6.3 Amgen Inc. Non-corticosteroid Immunomodulator Introduction
11.6.4 Amgen Inc. Revenue in Non-corticosteroid Immunomodulator Business (2018-2024)
11.6.5 Amgen Inc. Recent Development
11.7 Genentech, Inc.
11.7.1 Genentech, Inc. Company Detail
11.7.2 Genentech, Inc. Business Overview
11.7.3 Genentech, Inc. Non-corticosteroid Immunomodulator Introduction
11.7.4 Genentech, Inc. Revenue in Non-corticosteroid Immunomodulator Business (2018-2024)
11.7.5 Genentech, Inc. Recent Development
11.8 Pfizer Inc.
11.8.1 Pfizer Inc. Company Detail
11.8.2 Pfizer Inc. Business Overview
11.8.3 Pfizer Inc. Non-corticosteroid Immunomodulator Introduction
11.8.4 Pfizer Inc. Revenue in Non-corticosteroid Immunomodulator Business (2018-2024)
11.8.5 Pfizer Inc. Recent Development
11.9 Merck & Co., Inc.
11.9.1 Merck & Co., Inc. Company Detail
11.9.2 Merck & Co., Inc. Business Overview
11.9.3 Merck & Co., Inc. Non-corticosteroid Immunomodulator Introduction
11.9.4 Merck & Co., Inc. Revenue in Non-corticosteroid Immunomodulator Business (2018-2024)
11.9.5 Merck & Co., Inc. Recent Development
11.10 Sanofi S.A.
11.10.1 Sanofi S.A. Company Detail
11.10.2 Sanofi S.A. Business Overview
11.10.3 Sanofi S.A. Non-corticosteroid Immunomodulator Introduction
11.10.4 Sanofi S.A. Revenue in Non-corticosteroid Immunomodulator Business (2018-2024)
11.10.5 Sanofi S.A. Recent Development
11.11 Eli Lilly and Company
11.11.1 Eli Lilly and Company Company Detail
11.11.2 Eli Lilly and Company Business Overview
11.11.3 Eli Lilly and Company Non-corticosteroid Immunomodulator Introduction
11.11.4 Eli Lilly and Company Revenue in Non-corticosteroid Immunomodulator Business (2018-2024)
11.11.5 Eli Lilly and Company Recent Development
11.12 GlaxoSmithKline PLC
11.12.1 GlaxoSmithKline PLC Company Detail
11.12.2 GlaxoSmithKline PLC Business Overview
11.12.3 GlaxoSmithKline PLC Non-corticosteroid Immunomodulator Introduction
11.12.4 GlaxoSmithKline PLC Revenue in Non-corticosteroid Immunomodulator Business (2018-2024)
11.12.5 GlaxoSmithKline PLC Recent Development
11.13 Mylan Laboratories Inc.
11.13.1 Mylan Laboratories Inc. Company Detail
11.13.2 Mylan Laboratories Inc. Business Overview
11.13.3 Mylan Laboratories Inc. Non-corticosteroid Immunomodulator Introduction
11.13.4 Mylan Laboratories Inc. Revenue in Non-corticosteroid Immunomodulator Business (2018-2024)
11.13.5 Mylan Laboratories Inc. Recent Development
11.14 Glenmark Pharmaceuticals, Inc.
11.14.1 Glenmark Pharmaceuticals, Inc. Company Detail
11.14.2 Glenmark Pharmaceuticals, Inc. Business Overview
11.14.3 Glenmark Pharmaceuticals, Inc. Non-corticosteroid Immunomodulator Introduction
11.14.4 Glenmark Pharmaceuticals, Inc. Revenue in Non-corticosteroid Immunomodulator Business (2018-2024)
11.14.5 Glenmark Pharmaceuticals, Inc. Recent Development
11.15 Novartis AG
11.15.1 Novartis AG Company Detail
11.15.2 Novartis AG Business Overview
11.15.3 Novartis AG Non-corticosteroid Immunomodulator Introduction
11.15.4 Novartis AG Revenue in Non-corticosteroid Immunomodulator Business (2018-2024)
11.15.5 Novartis AG Recent Development
11.16 Zydus Cadila
11.16.1 Zydus Cadila Company Detail
11.16.2 Zydus Cadila Business Overview
11.16.3 Zydus Cadila Non-corticosteroid Immunomodulator Introduction
11.16.4 Zydus Cadila Revenue in Non-corticosteroid Immunomodulator Business (2018-2024)
11.16.5 Zydus Cadila Recent Development
11.17 Takeda Pharmaceutical Company Limited
11.17.1 Takeda Pharmaceutical Company Limited Company Detail
11.17.2 Takeda Pharmaceutical Company Limited Business Overview
11.17.3 Takeda Pharmaceutical Company Limited Non-corticosteroid Immunomodulator Introduction
11.17.4 Takeda Pharmaceutical Company Limited Revenue in Non-corticosteroid Immunomodulator Business (2018-2024)
11.17.5 Takeda Pharmaceutical Company Limited Recent Development
11.18 AstraZeneca PLC
11.18.1 AstraZeneca PLC Company Detail
11.18.2 AstraZeneca PLC Business Overview
11.18.3 AstraZeneca PLC Non-corticosteroid Immunomodulator Introduction
11.18.4 AstraZeneca PLC Revenue in Non-corticosteroid Immunomodulator Business (2018-2024)
11.18.5 AstraZeneca PLC Recent Development
11.19 Gilead Sciences, Inc.
11.19.1 Gilead Sciences, Inc. Company Detail
11.19.2 Gilead Sciences, Inc. Business Overview
11.19.3 Gilead Sciences, Inc. Non-corticosteroid Immunomodulator Introduction
11.19.4 Gilead Sciences, Inc. Revenue in Non-corticosteroid Immunomodulator Business (2018-2024)
11.19.5 Gilead Sciences, Inc. Recent Development
11.20 Boehringer Ingelheim GmbH
11.20.1 Boehringer Ingelheim GmbH Company Detail
11.20.2 Boehringer Ingelheim GmbH Business Overview
11.20.3 Boehringer Ingelheim GmbH Non-corticosteroid Immunomodulator Introduction
11.20.4 Boehringer Ingelheim GmbH Revenue in Non-corticosteroid Immunomodulator Business (2018-2024)
11.20.5 Boehringer Ingelheim GmbH Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Non-corticosteroid Immunomodulator Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Calcineurin Inhibitors
Table 3. Key Players of Antiproliferative Agents
Table 4. Key Players of mTOR Inhibitors
Table 5. Key Players of IMDH Inhibitors
Table 6. Key Players of Others
Table 7. Global Non-corticosteroid Immunomodulator Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Non-corticosteroid Immunomodulator Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global Non-corticosteroid Immunomodulator Market Size by Region (2018-2024) & (US$ Million)
Table 10. Global Non-corticosteroid Immunomodulator Market Share by Region (2018-2024)
Table 11. Global Non-corticosteroid Immunomodulator Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 12. Global Non-corticosteroid Immunomodulator Market Share by Region (2024-2029)
Table 13. Non-corticosteroid Immunomodulator Market Trends
Table 14. Non-corticosteroid Immunomodulator Market Drivers
Table 15. Non-corticosteroid Immunomodulator Market Challenges
Table 16. Non-corticosteroid Immunomodulator Market Restraints
Table 17. Global Non-corticosteroid Immunomodulator Revenue by Players (2018-2024) & (US$ Million)
Table 18. Global Non-corticosteroid Immunomodulator Market Share by Players (2018-2024)
Table 19. Global Top Non-corticosteroid Immunomodulator Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-corticosteroid Immunomodulator as of 2022)
Table 20. Ranking of Global Top Non-corticosteroid Immunomodulator Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Non-corticosteroid Immunomodulator Revenue (CR5 and HHI) & (2018-2024)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Non-corticosteroid Immunomodulator Product Solution and Service
Table 24. Date of Enter into Non-corticosteroid Immunomodulator Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Non-corticosteroid Immunomodulator Market Size by Type (2018-2024) & (US$ Million)
Table 27. Global Non-corticosteroid Immunomodulator Revenue Market Share by Type (2018-2024)
Table 28. Global Non-corticosteroid Immunomodulator Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 29. Global Non-corticosteroid Immunomodulator Revenue Market Share by Type (2024-2029)
Table 30. Global Non-corticosteroid Immunomodulator Market Size by Application (2018-2024) & (US$ Million)
Table 31. Global Non-corticosteroid Immunomodulator Revenue Market Share by Application (2018-2024)
Table 32. Global Non-corticosteroid Immunomodulator Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 33. Global Non-corticosteroid Immunomodulator Revenue Market Share by Application (2024-2029)
Table 34. North America Non-corticosteroid Immunomodulator Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. North America Non-corticosteroid Immunomodulator Market Size by Country (2018-2024) & (US$ Million)
Table 36. North America Non-corticosteroid Immunomodulator Market Size by Country (2024-2029) & (US$ Million)
Table 37. Europe Non-corticosteroid Immunomodulator Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. Europe Non-corticosteroid Immunomodulator Market Size by Country (2018-2024) & (US$ Million)
Table 39. Europe Non-corticosteroid Immunomodulator Market Size by Country (2024-2029) & (US$ Million)
Table 40. Asia-Pacific Non-corticosteroid Immunomodulator Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 41. Asia-Pacific Non-corticosteroid Immunomodulator Market Size by Region (2018-2024) & (US$ Million)
Table 42. Asia-Pacific Non-corticosteroid Immunomodulator Market Size by Region (2024-2029) & (US$ Million)
Table 43. Latin America Non-corticosteroid Immunomodulator Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Latin America Non-corticosteroid Immunomodulator Market Size by Country (2018-2024) & (US$ Million)
Table 45. Latin America Non-corticosteroid Immunomodulator Market Size by Country (2024-2029) & (US$ Million)
Table 46. Middle East & Africa Non-corticosteroid Immunomodulator Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 47. Middle East & Africa Non-corticosteroid Immunomodulator Market Size by Country (2018-2024) & (US$ Million)
Table 48. Middle East & Africa Non-corticosteroid Immunomodulator Market Size by Country (2024-2029) & (US$ Million)
Table 49. AbbVie Inc. Company Detail
Table 50. AbbVie Inc. Business Overview
Table 51. AbbVie Inc. Non-corticosteroid Immunomodulator Product
Table 52. AbbVie Inc. Revenue in Non-corticosteroid Immunomodulator Business (2018-2024) & (US$ Million)
Table 53. AbbVie Inc. Recent Development
Table 54. Bristol Myers Squibb Company Company Detail
Table 55. Bristol Myers Squibb Company Business Overview
Table 56. Bristol Myers Squibb Company Non-corticosteroid Immunomodulator Product
Table 57. Bristol Myers Squibb Company Revenue in Non-corticosteroid Immunomodulator Business (2018-2024) & (US$ Million)
Table 58. Bristol Myers Squibb Company Recent Development
Table 59. Celgene Corporation Company Detail
Table 60. Celgene Corporation Business Overview
Table 61. Celgene Corporation Non-corticosteroid Immunomodulator Product
Table 62. Celgene Corporation Revenue in Non-corticosteroid Immunomodulator Business (2018-2024) & (US$ Million)
Table 63. Celgene Corporation Recent Development
Table 64. Janssen Pharmaceuticals, Inc Company Detail
Table 65. Janssen Pharmaceuticals, Inc Business Overview
Table 66. Janssen Pharmaceuticals, Inc Non-corticosteroid Immunomodulator Product
Table 67. Janssen Pharmaceuticals, Inc Revenue in Non-corticosteroid Immunomodulator Business (2018-2024) & (US$ Million)
Table 68. Janssen Pharmaceuticals, Inc Recent Development
Table 69. Novartis AG Company Detail
Table 70. Novartis AG Business Overview
Table 71. Novartis AG Non-corticosteroid Immunomodulator Product
Table 72. Novartis AG Revenue in Non-corticosteroid Immunomodulator Business (2018-2024) & (US$ Million)
Table 73. Novartis AG Recent Development
Table 74. Amgen Inc. Company Detail
Table 75. Amgen Inc. Business Overview
Table 76. Amgen Inc. Non-corticosteroid Immunomodulator Product
Table 77. Amgen Inc. Revenue in Non-corticosteroid Immunomodulator Business (2018-2024) & (US$ Million)
Table 78. Amgen Inc. Recent Development
Table 79. Genentech, Inc. Company Detail
Table 80. Genentech, Inc. Business Overview
Table 81. Genentech, Inc. Non-corticosteroid Immunomodulator Product
Table 82. Genentech, Inc. Revenue in Non-corticosteroid Immunomodulator Business (2018-2024) & (US$ Million)
Table 83. Genentech, Inc. Recent Development
Table 84. Pfizer Inc. Company Detail
Table 85. Pfizer Inc. Business Overview
Table 86. Pfizer Inc. Non-corticosteroid Immunomodulator Product
Table 87. Pfizer Inc. Revenue in Non-corticosteroid Immunomodulator Business (2018-2024) & (US$ Million)
Table 88. Pfizer Inc. Recent Development
Table 89. Merck & Co., Inc. Company Detail
Table 90. Merck & Co., Inc. Business Overview
Table 91. Merck & Co., Inc. Non-corticosteroid Immunomodulator Product
Table 92. Merck & Co., Inc. Revenue in Non-corticosteroid Immunomodulator Business (2018-2024) & (US$ Million)
Table 93. Merck & Co., Inc. Recent Development
Table 94. Sanofi S.A. Company Detail
Table 95. Sanofi S.A. Business Overview
Table 96. Sanofi S.A. Non-corticosteroid Immunomodulator Product
Table 97. Sanofi S.A. Revenue in Non-corticosteroid Immunomodulator Business (2018-2024) & (US$ Million)
Table 98. Sanofi S.A. Recent Development
Table 99. Eli Lilly and Company Company Detail
Table 100. Eli Lilly and Company Business Overview
Table 101. Eli Lilly and Company Non-corticosteroid Immunomodulator Product
Table 102. Eli Lilly and Company Revenue in Non-corticosteroid Immunomodulator Business (2018-2024) & (US$ Million)
Table 103. Eli Lilly and Company Recent Development
Table 104. GlaxoSmithKline PLC Company Detail
Table 105. GlaxoSmithKline PLC Business Overview
Table 106. GlaxoSmithKline PLC Non-corticosteroid Immunomodulator Product
Table 107. GlaxoSmithKline PLC Revenue in Non-corticosteroid Immunomodulator Business (2018-2024) & (US$ Million)
Table 108. GlaxoSmithKline PLC Recent Development
Table 109. Mylan Laboratories Inc. Company Detail
Table 110. Mylan Laboratories Inc. Business Overview
Table 111. Mylan Laboratories Inc. Non-corticosteroid Immunomodulator Product
Table 112. Mylan Laboratories Inc. Revenue in Non-corticosteroid Immunomodulator Business (2018-2024) & (US$ Million)
Table 113. Mylan Laboratories Inc. Recent Development
Table 114. Glenmark Pharmaceuticals, Inc. Company Detail
Table 115. Glenmark Pharmaceuticals, Inc. Business Overview
Table 116. Glenmark Pharmaceuticals, Inc. Non-corticosteroid Immunomodulator Product
Table 117. Glenmark Pharmaceuticals, Inc. Revenue in Non-corticosteroid Immunomodulator Business (2018-2024) & (US$ Million)
Table 118. Glenmark Pharmaceuticals, Inc. Recent Development
Table 119. Novartis AG Company Detail
Table 120. Novartis AG Business Overview
Table 121. Novartis AG Non-corticosteroid Immunomodulator Product
Table 122. Novartis AG Revenue in Non-corticosteroid Immunomodulator Business (2018-2024) & (US$ Million)
Table 123. Novartis AG Recent Development
Table 124. Zydus Cadila Company Detail
Table 125. Zydus Cadila Business Overview
Table 126. Zydus Cadila Non-corticosteroid Immunomodulator Product
Table 127. Zydus Cadila Revenue in Non-corticosteroid Immunomodulator Business (2018-2024) & (US$ Million)
Table 128. Zydus Cadila Recent Development
Table 129. Takeda Pharmaceutical Company Limited Company Detail
Table 130. Takeda Pharmaceutical Company Limited Business Overview
Table 131. Takeda Pharmaceutical Company Limited Non-corticosteroid Immunomodulator Product
Table 132. Takeda Pharmaceutical Company Limited Revenue in Non-corticosteroid Immunomodulator Business (2018-2024) & (US$ Million)
Table 133. Takeda Pharmaceutical Company Limited Recent Development
Table 134. AstraZeneca PLC Company Detail
Table 135. AstraZeneca PLC Business Overview
Table 136. AstraZeneca PLC Non-corticosteroid Immunomodulator Product
Table 137. AstraZeneca PLC Revenue in Non-corticosteroid Immunomodulator Business (2018-2024) & (US$ Million)
Table 138. AstraZeneca PLC Recent Development
Table 139. Gilead Sciences, Inc. Company Detail
Table 140. Gilead Sciences, Inc. Business Overview
Table 141. Gilead Sciences, Inc. Non-corticosteroid Immunomodulator Product
Table 142. Gilead Sciences, Inc. Revenue in Non-corticosteroid Immunomodulator Business (2018-2024) & (US$ Million)
Table 143. Gilead Sciences, Inc. Recent Development
Table 144. Boehringer Ingelheim GmbH Company Detail
Table 145. Boehringer Ingelheim GmbH Business Overview
Table 146. Boehringer Ingelheim GmbH Non-corticosteroid Immunomodulator Product
Table 147. Boehringer Ingelheim GmbH Revenue in Non-corticosteroid Immunomodulator Business (2018-2024) & (US$ Million)
Table 148. Boehringer Ingelheim GmbH Recent Development
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-corticosteroid Immunomodulator Market Size Comparison by Type (2024-2029) & (US$ Million)
Figure 2. Global Non-corticosteroid Immunomodulator Market Share by Type: 2022 VS 2029
Figure 3. Calcineurin Inhibitors Features
Figure 4. Antiproliferative Agents Features
Figure 5. mTOR Inhibitors Features
Figure 6. IMDH Inhibitors Features
Figure 7. Others Features
Figure 8. Global Non-corticosteroid Immunomodulator Market Size Comparison by Application (2024-2029) & (US$ Million)
Figure 9. Global Non-corticosteroid Immunomodulator Market Share by Application: 2022 VS 2029
Figure 10. Organ Transplantation Case Studies
Figure 11. Atopic Dermatitis Case Studies
Figure 12. Crohn's Disease Case Studies
Figure 13. Ulcerative Colitis Case Studies
Figure 14. Others Case Studies
Figure 15. Non-corticosteroid Immunomodulator Report Years Considered
Figure 16. Global Non-corticosteroid Immunomodulator Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 17. Global Non-corticosteroid Immunomodulator Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 18. Global Non-corticosteroid Immunomodulator Market Share by Region: 2022 VS 2029
Figure 19. Global Non-corticosteroid Immunomodulator Market Share by Players in 2022
Figure 20. Global Top Non-corticosteroid Immunomodulator Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-corticosteroid Immunomodulator as of 2022)
Figure 21. The Top 10 and 5 Players Market Share by Non-corticosteroid Immunomodulator Revenue in 2022
Figure 22. North America Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. North America Non-corticosteroid Immunomodulator Market Share by Country (2018-2029)
Figure 24. United States Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Canada Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Europe Non-corticosteroid Immunomodulator Market Share by Country (2018-2029)
Figure 28. Germany Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. France Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. U.K. Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Italy Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Russia Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Nordic Countries Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Asia-Pacific Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Asia-Pacific Non-corticosteroid Immunomodulator Market Share by Region (2018-2029)
Figure 36. China Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Japan Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. South Korea Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Southeast Asia Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. India Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Australia Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Latin America Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Latin America Non-corticosteroid Immunomodulator Market Share by Country (2018-2029)
Figure 44. Mexico Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Brazil Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Middle East & Africa Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Middle East & Africa Non-corticosteroid Immunomodulator Market Share by Country (2018-2029)
Figure 48. Turkey Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Saudi Arabia Non-corticosteroid Immunomodulator Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. AbbVie Inc. Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2018-2024)
Figure 51. Bristol Myers Squibb Company Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2018-2024)
Figure 52. Celgene Corporation Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2018-2024)
Figure 53. Janssen Pharmaceuticals, Inc Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2018-2024)
Figure 54. Novartis AG Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2018-2024)
Figure 55. Amgen Inc. Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2018-2024)
Figure 56. Genentech, Inc. Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2018-2024)
Figure 57. Pfizer Inc. Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2018-2024)
Figure 58. Merck & Co., Inc. Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2018-2024)
Figure 59. Sanofi S.A. Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2018-2024)
Figure 60. Eli Lilly and Company Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2018-2024)
Figure 61. GlaxoSmithKline PLC Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2018-2024)
Figure 62. Mylan Laboratories Inc. Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2018-2024)
Figure 63. Glenmark Pharmaceuticals, Inc. Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2018-2024)
Figure 64. Novartis AG Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2018-2024)
Figure 65. Zydus Cadila Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2018-2024)
Figure 66. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2018-2024)
Figure 67. AstraZeneca PLC Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2018-2024)
Figure 68. Gilead Sciences, Inc. Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2018-2024)
Figure 69. Boehringer Ingelheim GmbH Revenue Growth Rate in Non-corticosteroid Immunomodulator Business (2018-2024)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed